129 related articles for article (PubMed ID: 16339691)
1. Murine and math models for the level of stable mixed chimerism to cure beta-thalassemia by nonmyeloablative bone marrow transplantation.
Roberts C; Kean L; Archer D; Balkan C; Hsu LL
Ann N Y Acad Sci; 2005; 1054():423-8. PubMed ID: 16339691
[TBL] [Abstract][Full Text] [Related]
2. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
3. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model.
Ploemacher RE; Johnson KW; Rombouts EJ; Etienne K; Westerhof GR; Baumgart J; White-Scharf ME; Down JD
Biol Blood Marrow Transplant; 2004 Apr; 10(4):236-45. PubMed ID: 15077222
[TBL] [Abstract][Full Text] [Related]
4. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease.
Kean LS; Manci EA; Perry J; Balkan C; Coley S; Holtzclaw D; Adams AB; Larsen CP; Hsu LL; Archer DR
Blood; 2003 Dec; 102(13):4582-93. PubMed ID: 12933586
[TBL] [Abstract][Full Text] [Related]
5. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling.
Lisini D; Zecca M; Giorgiani G; Montagna D; Cristantielli R; Labirio M; Grignani P; Previderè C; Di Cesare-Merlone A; Amendola G; Bergami E; Mastronuzzi A; Maccario R; Locatelli F
Haematologica; 2008 Dec; 93(12):1859-67. PubMed ID: 18945748
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. A murine model of antimetabolite-based, submyeloablative conditioning for bone marrow transplantation: biologic insights and potential applications.
Goebel WS; Pech NK; Meyers JL; Srour EF; Yoder MC; Dinauer MC
Exp Hematol; 2004 Dec; 32(12):1255-64. PubMed ID: 15588950
[TBL] [Abstract][Full Text] [Related]
8. Application of chimerism-based drug-induced tolerance to rat into mouse xenotransplantation.
Tomita Y; Shimizu I; Iwai T; Zhang QW; Okano S; Kajiwara T; Onzuka T; Tominaga R
Scand J Immunol; 2006 Oct; 64(4):392-7. PubMed ID: 16970680
[TBL] [Abstract][Full Text] [Related]
9. Induction of mixed chimerism through transplantation of CD45-congenic mobilized peripheral blood stem cells after nonmyeloablative irradiation.
Koporc Z; Bigenzahn S; Blaha P; Fariborz E; Selzer E; Sykes M; Muehlbacher F; Wekerle T
Biol Blood Marrow Transplant; 2006 Mar; 12(3):284-92. PubMed ID: 16503497
[TBL] [Abstract][Full Text] [Related]
10. Full chimerism in nonmyeloablative stem cell transplantation in a beta-thalassemia major patient (class 3 Lucarelli).
Hongeng S; Chuansumrit A; Hathirat P; Rerkamnuaychoke B; Chaisiripoomkere W; Jootar S
Bone Marrow Transplant; 2002 Sep; 30(6):409-10. PubMed ID: 12235528
[TBL] [Abstract][Full Text] [Related]
11. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
12. Correction of murine beta-thalassemia by partial bone marrow chimerism: selective advantage of normal erythropoiesis.
van den Bos C; Kieboom D; Wagemaker G
Bone Marrow Transplant; 1993 Jul; 12(1):9-13. PubMed ID: 8374541
[TBL] [Abstract][Full Text] [Related]
13. Selective advantage of normal erythrocyte production after bone marrow transplantation of alpha-thalassemic mice.
van den Bos C; Kieboom D; van der Sluijs JP; Baert MR; Ploemacher RE; Wagemaker G
Exp Hematol; 1994 May; 22(5):441-6. PubMed ID: 8174674
[TBL] [Abstract][Full Text] [Related]
14. Influence of the conditioning regimens on the incidence of mixed chimerism in thalassemic transplanted patients.
Manna M; Nesci S; Andreani M; Tonucci P; Lucarelli G
Bone Marrow Transplant; 1993; 12 Suppl 1():70-3. PubMed ID: 8104074
[No Abstract] [Full Text] [Related]
15. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation.
Andreani M; Nesci S; Lucarelli G; Tonucci P; Rapa S; Angelucci E; Persini B; Agostinelli F; Donati M; Manna M
Bone Marrow Transplant; 2000 Feb; 25(4):401-4. PubMed ID: 10723583
[TBL] [Abstract][Full Text] [Related]
16. Successful correction of murine sickle cell disease with reduced stem cell requirements reinforced by fractionated marrow infusions.
Felfly H; Trudel M
Br J Haematol; 2010 Feb; 148(4):646-58. PubMed ID: 19930185
[TBL] [Abstract][Full Text] [Related]
17. Anti-mouse CD154 antibody treatment facilitates generation of mixed xenogeneic rat hematopoietic chimerism, prevents wasting disease and prolongs xenograft survival in mice.
Masaki H; Appel MC; Leahy L; Leif J; Paquin L; Shultz LD; Mordes JP; Greiner DL; Rossini AA
Xenotransplantation; 2006 May; 13(3):224-32. PubMed ID: 16756565
[TBL] [Abstract][Full Text] [Related]
18. Induction of tolerance in quadruple chimeric mice.
Fan TX; Hisha H; Jin TN; Sugiura K; Inaba M; Yang GX; Li Q; Wang XL; Song CY; Cui YZ; Li Q; Zhang Y; Zhang XG; Fan HX; Ikehara S
Stem Cells; 2004; 22(5):683-95. PubMed ID: 15342933
[TBL] [Abstract][Full Text] [Related]
19. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation.
Kean LS; Durham MM; Adams AB; Hsu LL; Perry JR; Dillehay D; Pearson TC; Waller EK; Larsen CP; Archer DR
Blood; 2002 Mar; 99(5):1840-9. PubMed ID: 11861303
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation.
Saito TI; Rubio MT; Sykes M
Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
